The price of this UK tech share is up over 80% in just the last month. Would I buy?

This UK tech share, which provides artificial intelligence diagnostics, has leapt recently in price and there could be potentially a lot more growth on the horizon.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

There’s a perception that the US has all the high-growth technology stocks in the US and that UK tech shares tend to be bought by overseas companies. For example, SoftBank bought ARM Holdings back in 2016. And now Nvidia is taking it over. However, the UK does have listed technology shares

One of these shares is artificial intelligence company RenalytixAI (LSE: RENX). The share price has leapt recently, which raises the question: could the shares rocket further or are they now too expensive?

What does the company do?

First of all, let’s look at what it does. RenalytixAI provides artificial intelligence-based diagnostics for kidney disease through its KidneyIntelX platform. The algorithm combines data in order to provide a patient risk score which then helps doctors treat patients better.

It has a niche which is actually quite a large addressable market, especially in the US. Chronic kidney conditions there affect 15% of adults or 37m people. This costs Medicare over $120bn per year.

Obviously, the problem stretches beyond the US and is global, so there’s a huge potential market for an AI diagnostics tool to help doctors.

Why has the share price risen and what’s the opportunity for future growth?

I think it’s the potential for the company to get approval from the US Food and Drug Administration (FDA) that is boosting the shares. Approvals to sell its tests at $950 a time to healthcare facilities across the US could be transformative for the company, which makes no revenue for now. An update is expected within the coming months, hence the share price leap. 

Beyond the immediate prospect of the FDA announcement, the AI company has partnerships with AstraZeneca and Mount Sinai in the US. The latter is a joint venture for a Covid-19 test, which could be rolled out globally. That could be another source of revenue in the future. 

Longer term, if RenalytixAI can roll out successfully across the US there could be huge opportunities in other international markets. Also in the future, there will almost certainly be more chances to apply artificial intelligence to other healthcare problems. Once the technology is accepted and trusted there will be a lot of other opportunities to cut healthcare costs and improve outcomes for patients. Spending on solutions at that point should accelerate quickly. 

What will I do with this UK tech share?

For now when it comes to the share price, I’ll wait and see. When a share price rises this much in such a short space of time there’s certainly more risk. I worry I may be late to the party and arrive just as the share price starts to revert back towards more usual levels. 

I’ll add the UK tech share to my watchlist and see what happens next. It’s possible, of course, the FDA might not rule in favour of RenalytixAI, or other operational hurdles may appear. That’s why I remain quietly optimistic, but also cautious.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Andy Ross owns no share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Close-up of a woman holding modern polymer ten, twenty and fifty pound notes.
Growth Shares

This FTSE 250 stock has beaten the index by around 10x over the last year

Jon Smith rates a FTSE 250 stock that has smashed the broader index performance and could keep going based on…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

B&M shares are at record lows! Is now the time to consider buying?

The retailer, demoted from the FTSE 100 to the FTSE 250 last year, continues to struggle. But are B&M shares…

Read more »

Investing For Beginners

2 reasons why the stock market could hit 10,000 points by December

Jon Smith explains how the makeup of the UK stock market and the current valuation could support a move towards…

Read more »

Queen Street, one of Cardiff's main shopping streets, busy with Saturday shoppers.
Investing Articles

Why this FTSE 100 rocket is this investment trust’s number 1 holding

A UK investment trust is certainly going against the grain by having this FTSE 100 share as a high-conviction holding…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

These 2 FTSE growth stocks jumped 8% and 4.5% today!

Ben McPoland takes a closer look at a pair of FTSE stocks that are performing really well recently. Why are…

Read more »

Road 2025 to 2032 new year direction concept
Investing Articles

This under‑the‑radar FTSE 100 growth stock is also a secret dividend superstar!

Harvey Jones belatedly wakes up to a brilliant FTSE 100 growth stock that has an equally remarkable track record of…

Read more »

Business manager working at a pub doing the accountancy and some paperwork using a laptop computer
Investing Articles

Barratt Redrow share price plunges 9% on profits hit – time to consider buying?

Harvey Jones says FTSE 100 housebuilders continue to suffer with the Barratt Redrow share price slumping on a profit warning.…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Growth Shares

Why the next month could make or break the Lloyds share price

Jon Smith outlines two key events in coming weeks that could influence the Lloyds share price, leading him to make…

Read more »